Ribo Life Science Reaches Third Milestone in Pre-clinical siRNA Partnership with Boehringer Ingelheim

Bulletin Express

May 06

On 6 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the attainment of the third key milestone in its research collaboration with Germany-based Boehringer Ingelheim. The partnership, initiated to discover small-interfering RNA (siRNA) therapies for liver diseases, is focused on metabolic dysfunction-associated steatohepatitis (MASH)—a progressive form of fatty-liver disease that threatens more than 200 million patients worldwide with risks of fibrosis, cirrhosis, liver failure and liver cancer.

The milestone underscores the commercial potential of Ribo Life Science’s siRNA platform and further strengthens its standing as a preferred research partner for multinational pharmaceutical companies. While specific scientific details and financial terms were not disclosed, the company highlighted that the programme remains in the pre-clinical phase. Consequently, there is no certainty the collaboration will culminate in a marketable therapy.

Ribo Life Science’s board reiterated the need for shareholder and investor caution when dealing in the company’s securities, given the inherent uncertainties of early-stage drug development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1134971944"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1134971944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1134971944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 08:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134971944","market":"hk","top_or_hot":-1,"title":"Ribo Life Science Reaches Third Milestone in Pre-clinical siRNA Partnership with Boehringer Ingelheim","media":"Bulletin Express","content":"<p>On 6 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the attainment of the third key milestone in its research collaboration with Germany-based Boehringer Ingelheim. The partnership, initiated to discover small-interfering RNA (siRNA) therapies for liver diseases, is focused on metabolic dysfunction-associated steatohepatitis (MASH)—a progressive form of fatty-liver disease that threatens more than 200 million patients worldwide with risks of fibrosis, cirrhosis, liver failure and liver cancer.</p>\n<p>The milestone underscores the commercial potential of Ribo Life Science’s siRNA platform and further strengthens its standing as a preferred research partner for multinational pharmaceutical companies. While specific scientific details and financial terms were not disclosed, the company highlighted that the programme remains in the pre-clinical phase. Consequently, there is no certainty the collaboration will culminate in a marketable therapy.</p>\n<p>Ribo Life Science’s board reiterated the need for shareholder and investor caution when dealing in the company’s securities, given the inherent uncertainties of early-stage drug development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ribo Life Science Reaches Third Milestone in Pre-clinical siRNA Partnership with Boehringer Ingelheim</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRibo Life Science Reaches Third Milestone in Pre-clinical siRNA Partnership with Boehringer Ingelheim\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 08:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 6 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the attainment of the third key milestone in its research collaboration with Germany-based Boehringer Ingelheim. The partnership, initiated to discover small-interfering RNA (siRNA) therapies for liver diseases, is focused on metabolic dysfunction-associated steatohepatitis (MASH)—a progressive form of fatty-liver disease that threatens more than 200 million patients worldwide with risks of fibrosis, cirrhosis, liver failure and liver cancer.</p>\n<p>The milestone underscores the commercial potential of Ribo Life Science’s siRNA platform and further strengthens its standing as a preferred research partner for multinational pharmaceutical companies. While specific scientific details and financial terms were not disclosed, the company highlighted that the programme remains in the pre-clinical phase. Consequently, there is no certainty the collaboration will culminate in a marketable therapy.</p>\n<p>Ribo Life Science’s board reiterated the need for shareholder and investor caution when dealing in the company’s securities, given the inherent uncertainties of early-stage drug development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1134971944","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134971944","pubTimestamp":1778025764,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 6 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the attainment of the third key milestone in its research collaboration with Germany-based Boehringer Ingelheim. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"Ribo Life Science与勃林格殷格翰的临床前siRNA合作达到第三个里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"On 6 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the attainment of the third key milestone in its research collaboration with Germany-based Boehringer Ingelheim. The partnership, initiated to discover small-interfering RNA (siRNA) therapies for liver diseases, is focused on metabolic dysfunction-associated steatohepatitis (MASH)—a progressive form of fatty-liver disease that threatens more than 200 million patients worldwide with risks of fibrosis, cirrhosis, liver failure and liver cancer.\nThe milestone underscores the commercial potential of Ribo Life Science’s siRNA platform and further strengthens its standing as a preferred research partner for multinational pharmaceutical companies. While specific scientific details and financial terms were not disclosed, the company highlighted that the programme remains in the pre-clinical phase. Consequently, there is no certainty the collaboration will culminate in a marketable therapy.\nRibo Life Science’s board reiterated the need for shareholder and investor caution when dealing in the company’s securities, given the inherent uncertainties of early-stage drug development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}